What Do We Really Know About the Effect of Prolonged Heart Rhythm Monitoring After Stroke?

Area of Science:

• Cardiology
• Neurology
• Clinical Medicine

Background:

• Current understanding of atrial fibrillation (AF)-associated stroke risk and anticoagulation benefits primarily comes from patients with clinically diagnosed AF.
• Subclinical atrial fibrillation (SCAF), detected via prolonged heart monitoring, is often asymptomatic and linked to higher stroke risk, potentially progressing to clinical AF.

Purpose of the Study:

• To evaluate the net benefit of screening for and treating subclinical atrial fibrillation (SCAF), particularly in secondary stroke prevention.
• To interpret recent findings on SCAF in the context of post-stroke AF screening and prevention strategies.

Main Methods:

• Review and synthesis of recent studies investigating subclinical atrial fibrillation (SCAF).
• Analysis of stroke risk, prevalence, and progression associated with SCAF compared to clinically detected AF and sinus rhythm.
• Assessment of the balance between stroke risk reduction and bleeding risk from anticoagulation in SCAF patients.

Main Results:

• Subclinical atrial fibrillation (SCAF) is highly prevalent and can sometimes represent physiological findings.
• The stroke risk associated with SCAF is lower than that of clinically detected atrial fibrillation.
• The potential benefits of anticoagulation for stroke risk reduction in SCAF may be offset by an increased risk of bleeding, resulting in no clear net benefit.

Conclusions:

• The established practice of extensive screening for and treatment of subclinical atrial fibrillation (SCAF) requires re-evaluation.
• The interpretation of SCAF findings necessitates careful consideration of its lower stroke risk and the potential for increased bleeding complications.
• Further research is needed to define optimal management strategies for subclinical atrial fibrillation in the context of stroke prevention.